Clinical Trial Update: Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating spironolactone in hemodialysis patients has completed, assessing its impact on cardio- and cerebrovascular morbidity and mortality in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Cerebrovascular Disease
• End-stage Renal Disease

Drugs mentioned

• Spironolactone (spironolactone)

Snippet

Sponsor: Dialysis Outcomes Heart Failure Aldactone Study Group | Conditions: End-stage Renal Failure | Phase 4 | Status: COMPLETED